Wear Reduction Device for Rotary Solids Handling Equipment

A pump for solids handling is provided having a suction liner in combination with an impeller. The suction liner has a suction liner spiral design. The impeller has forward curved impeller suction side pump out vanes. The suction liner spiral design and the forward curved impeller suction side pump out vanes are configured to handle solids substantially having a weight concentration (Cw)<about 40% and/or a solids size distribution <about 200 microns, and to exclude abrasive solids from an impeller/suction side liner gap by increasing the resistance to slurry flow from a high pressure area at the periphery of the impeller periphery, and expel the solids which do manage to enter the impeller/suction side liner gap by guiding the solids away from a suction eye of the impeller, so abrasive erosion is substantially prevented to significantly reduce wear and a tight clearance is substantially maintained at the impeller/suction side liner gap between the impeller and the suction liner, which prevents degradation of pump performance through excessive leakage.

Anhydrate Forms Of A Pyridine Derivative

The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

BIOMECHANICAL INFORMATION DETERMINATION

Systems and methods of the present disclosure may include initializing a first plurality of inertial measurement units (IMUs) and a second plurality of IMUs, and attaching the first plurality of IMUs to a first segment of a subject and the second plurality of IMUs to a second segment of the subject. Such a method may also include obtaining data from the first plurality of IMUs and the second plurality of IMUs as the subject performs a motion, and determining an absolute position of the first segment and the second segment based on the data. 1. A method comprising:recording first initial orientation information of a first inertial measurement unit (IMU) placed in a first initialization position at a first initialization location;recording second initial orientation information of a second IMU placed in a second initialization position at a second initialization location;placing the first IMU on a first segment of a subject;placing the second IMU on a second segment of the subject, wherein the first segment and the second segment move relative to each other about a joint of the subject;recording first acceleration information output by the first IMU in a continuous manner after recordation of the first initial orientation information of the first IMU;recording second acceleration information output by the second IMU in a continuous manner after recordation of the second initial orientation information of the second IMU;determining a first absolute location of the first segment with respect to the first initialization location based on the first acceleration information and the first initial orientation information;determining a second absolute location of the second segment with respect to the second initialization location based on the second acceleration information and the second initial orientation information; anddetermining kinematics of the first segment and the second segment with respect to the joint based on the first absolute location and the second ...

SUBSTANCE OR CONTAMINATION DETECTION

A spectroscopic method and system detects the amount of one or more substances or contaminants in or on a product, such as fecal contamination on meat samples. 1. A method for determining the amount of one or more substances or contaminants in or on an illuminated product , the method comprising the steps of:receiving a first signal indicative of intensity of light emitted from the product across a first waveband,receiving a second signal indicative of intensity of light emitted from the product across a second waveband containing one or more wavelengths associated with the fluorescent properties of the contaminants or substances to be detected,determining or predicting a value indicative of an amount of the substance or contaminant, for each of, or at least one of, the one or more substances or contaminants in or on the product, from the first and second signals and from predetermined information relating to fluorescence behaviour of a same or similar product or a main or more abundant substance of the product isolated from the substance or contaminant (hereinafter referred to as isolated product) and/or relating to the fluorescence behaviour of the substance or contaminant isolated from the product.2. The method as claimed in wherein the second waveband is within the first waveband.3. The method as claimed in wherein the second waveband is outside the first waveband.4. The method as claimed in any one of to wherein the step of determining or predicting the value indicative of the amount of the substance or contaminant comprises:separating from the first signal a portion of the signal relating to the substance or contaminant based on: the second signal, the fluorescent behaviour of the substance or contaminant in isolation from the product and the fluorescent behaviour of the isolated product.5. The method as claimed in any one of to further comprising determining or predicting a value indicative of an amount of a main or more abundant substance of the product by ...

Hydrogen Production System and Process

Hydrogen production process and apparatus using a combined stream of gas turbine exhaust from a gas turbine and combustion air from forced draft fan as combustion oxidant in a steam reforming furnace. A valve assembly for providing draft air is included to quickly provide additional combustion air to the reformer furnace when the gas turbine unexpectedly shuts down. 1. An apparatus for producing a H-containing product , the apparatus comprising:a gas turbine having an outlet for withdrawing an exhaust stream from the gas turbine;a forced draft fan having an outlet for discharging an oxidant stream;a valve assembly for providing a draft air stream;a reformer furnace operatively connected to the gas turbine, the forced draft fan, and the valve assembly, and operatively disposed to receive at least a portion of the exhaust stream from the gas turbine, at least a portion of the oxidant stream from the forced draft fan, and the draft air stream from the valve assembly; anda heat exchanger operatively disposed between the forced draft fan and the reformer furnace, wherein the heat exchanger is operatively disposed to receive the at least a portion of the oxidant stream from the forced draft fan, and the reformer furnace is operatively disposed to receive the at least a portion of the oxidant stream from the heat exchanger.2. The apparatus of further comprising:a second forced draft fan having an outlet for discharging a second oxidant stream;a second valve assembly for providing a second draft air stream; anda second reformer furnace operatively connected to the gas turbine, the second forced draft fan, and the second valve assembly, and operatively disposed to receive a second portion of the exhaust stream from the gas turbine, at least a portion of the second oxidant stream from the second forced draft fan, and the second draft air stream from the second valve assembly; anda second heat exchanger operatively disposed between the second forced draft fan and the second ...

Method and Apparatus for Producing a Hydrogen-Containing Product

Process and apparatus for producing a hydrogen-containing product by steam-hydrocarbon reforming of multiple hydrocarbon feedstocks in a production facility utilizing a prereformer in addition to the primary reformer. The temperature of the reactant mixture introduced into the prereformer is controlled depending on the composition of the reactant mixture fed to the prereformer. 2. The process of wherein during the first time period the process further comprises:passing the second fraction of the first reactant gas mixture from the bypass conduit to the catalyst-containing reactor, introducing the second fraction of the first reactant gas mixture into the catalyst-containing reactor as at least another portion of the feed to the catalyst-containing reactor, reacting the second fraction of the first reactant gas mixture in the catalyst-containing reactor, wherein the effluent from the catalyst-containing reactor is also formed from the second fraction of the first reactant gas mixture.3. The process of wherein during the second time period the process further comprises:passing the second fraction of the second reactant gas mixture from the heat exchanger to the catalyst-containing reactor, introducing the second fraction of the second reactant gas mixture into the catalyst-containing reactor as at least another portion of the feed to the catalyst-containing reactor, reacting the second fraction of the second reactant gas mixture in the catalyst-containing reactor, wherein the effluent from the catalyst-containing reactor is also formed from the second fraction of the second reactant gas mixture .4. The process ofwherein the first fraction or all of the first reactant gas mixture is cooled in the heat exchanger by indirect heat exchange with boiler feed water.5. The process ofwherein when passing the first fraction or all of the first reactant gas mixture from the heat exchanger to the catalyst-containing reactor, the first fraction or all of the first reactant gas ...

Methods and Apparatuses to Facilitate Protection of Sensitive Data Online and Reduce Exposure in the Event of a Data Breach

The present invention can provide a system to facilitate encryption/decryption of sensitive data/information online. It will revolutionize the way data is encrypted because it provides a way for individuals to discretely protect their data both at rest and in motion, and it allows users the ability to decide whom the data are shared with. The present invention can become valuable to businesses and companies by reducing the exposure of sensitive information in the event of a data breach, and by extension it reduces costs related to recovering from a data breach. 1(a) User determines form fields on documents/images which will be made available for decryption;(b) Data is encrypted at rest and in transit;(c) Encrypted version of forms/documents/images are stored on platform servers;(d) User can share entire encrypted files or select portions thereof to be shared with others by generating an assigned public key; and(e) User can store encrypted files on platform servers for a finite period or for an extended timeframe.. A tool for providing client-side, granular encryption of data on forms/documents/images comprising: This application claims priority to U.S. provisional application 62/370,635 filed Aug. 3, 2016, which is incorporated herein by reference.The present invention relates to cryptography, encryption/decryption, steganography and the protection of online data in documents and images, both in motion and at rest.Embodiments of the present invention provide Client-Side Encryption, Form Field Encryption, Steganography using Fortezza for Randomizing Data and DNA as Decryption Key with Blockchain as a granular time stamp.Systems currently in place to handle the safekeeping of sensitive, personal data online have not evolved to keep pace with the number of data breaches happening on a regular basis. Whether breaches are perpetrated by hackers, or as the result of poor business practices, many companies responsible for protecting our personal information do not provide ...

A FRUIT PACKAGING TRAY, APPARATUS AND PROCESS

Embodiments of the invention provide a packaging tray for use in packaging items, the tray having a first region having a cross-section which defines a concave surface having one or more cross-sections suitable to receive an item and a second region having a cross-section which is substantially straight. Embodiments provide a process in which tray may be loaded by depositing kiwi fruit and then agitated to settle and align the kiwifruit in the concave sections assisted with the straight sections providing space for movement of the kiwifruit laterally to the concave sections and directing the kiwifruit of the agitated tray towards the concave section. The tray is wrapped after the items are deposited and the wrapped tray is loaded into a box with settled items and loads the wrapped tray into a box. 1. A process of packaging items comprising:depositing items onto a tray having pockets for individual items;wrapping the tray and deposited items with a sheet of wrapping material; andloading the wrapped tray into a box which defines a tray cavity to receive the tray with deposited items, wherein the wrapped tray is conveyed to a leading edge of the box which is conveyed in synch with the tray to retain items in the pockets as the tray is deposited into the tray cavity.2. The process of claim 1 , wherein the tray is flexible.3. The process of claim 1 , wherein each pocket of the tray has a settling region adjacent to the bed claim 1 , wherein the tray has one or more pocket-separating surfaces extending between respective two or more pockets; and wherein the settling region is defined by a settling surface directed away from the bed to the pocket-separating surface to allow space within a pocket for an item to move laterally with respect to the bed under agitation of the item relative to the tray claim 1 , and wherein the bedding surface terminates and the settling surface starts at a point below a centreline of the shape characteristic of an item received in a pocket.4. ...

METHOD OF FORMING A CONTAINMENT SYSTEM FOR AN ABSORBENT ARTICLE

A method of forming a containment system for an absorbent article that includes a front end region, rear end region, a first elasticized leg cuff and a second elasticized leg cuff. The method includes providing a first containment flap and a second containment flap that can each include a stem, an inner flap projection, and an outer flap projection. The method can further include securing the outer flap projection of the first containment flap in at least a portion of at least one of the front end region and the rear end region and securing the outer flap projection of the second containment flap in at least a portion of at least one of the front end region and the rear end region. 1. A method of forming a containment system for an absorbent article comprising a first containment flap and a second containment flap each including a stem , an inner flap projection extending away from the stem , and an outer flap projection extending away from the stem and the inner flap projection , the absorbent article including a body facing liner , a backsheet coupled to the body facing liner , and an absorbent body positioned between the body facing liner and the backsheet , the method comprising:providing a substrate having a first surface and a second surface, the first surface being opposite the second surface, the substrate including a first half and a second half divided by a centerline, the first half being on a first side of the centerline and the second half being on a second side of the centerline;attaching a first elastic member to the first surface in the first half of the substrate;attaching a second elastic member to the first surface in the second half of the substrate;folding a first portion of the first half of the substrate over the first elastic member towards the centerline;folding a first portion of the second half of the substrate over the second elastic member towards the centerline;folding a second portion of the first half of the substrate towards the ...

ABSORBENT ARTICLE WITH CONTAINMENT FLAPS

An absorbent article having a first containment flap and a second containment flap each having a stem, an inner flap projection, and an outer flap projection. The stems of the first and the second containment flaps can be positioned laterally inward of the longitudinal side edges of the absorbent article. The stem can extend away from the body facing liner when the absorbent article is in a relaxed condition. The inner flap projection can extend laterally from the stem towards a longitudinal axis of the absorbent article and the outer flap projection can extend laterally from the stem away from the longitudinal axis and the inner flap projection when the article is in a relaxed condition. The outer flap projection can be bonded to the stem in at least a portion of one of the front waist region and the rear waist region. 1. An absorbent article comprising:a longitudinal axis and a lateral axis;a front waist region, a rear waist region, a crotch region, the crotch region being disposed between the front waist region and the rear waist region;a front waist edge in the front waist region, a rear waist edge in the rear waist region, a first longitudinal side edge and a second longitudinal side edge, the first longitudinal side edge and the second longitudinal side edge each extending from the front waist edge to the rear waist edge;a body facing liner comprising a body facing surface and a garment facing surface;a backsheet coupled to the body facing liner;an absorbent body positioned between the body facing liner and the backsheet; and a stem bonded to one of the body facing liner and the backsheet, the stem configured to extend away from the body facing surface of the body facing liner and the backsheet in at least the crotch region when the absorbent article is in a relaxed condition;', 'an inner flap projection extending laterally from the stem towards the longitudinal axis when the absorbent article is in the relaxed condition, at least a portion of the inner flap ...

Method and Apparatus for Producing a Hydrogen-Containing Product

Process and apparatus for producing a hydrogen-containing product by steam-hydrocarbon reforming of multiple hydrocarbon feedstocks in a production facility utilizing a prereformer in addition to the primary reformer. The temperature of the reactant mixture introduced into the prereformer is controlled depending on the composition of the reactant mixture fed to the prereformer.

OIL-IN-WATER EMULSIONS

The invention relates to an oil-in-water emulsion comprising an oil phase and an aqueous phase, and a primary surfactant, wherein the oil phase is dispersed in the aqueous phase, and wherein the oil-in-water emulsion has: an average droplet size distribution (D[4,3]) in the range of from 3 to 15 μm and less than 3 wt % of the droplets have a particle size of greater than 125 μm; a viscosity of greater than 100 and up to 700 mPas at 50° C.±10% and 20 s±10%; and a static stability of less than 5% residue after centrifugation at 50° C.±10% and 2000 g=10% for 30 minutes±10%. A process for preparing such an oil-in-water emulsion comprises preparing an aqueous phase comprising a primary surfactant, heating a hydrocarbon-containing oil-phase, and blending the hydrocarbon-containing oil and the aqueous phase under conditions sufficient to form an oil-in-water emulsion. The invention also relates to methods for determining the static and dynamic stability of oil-in-water emulsions. Static stability can be determined by a method comprising the steps of: providing an oil-in-water emulsion; centrifuging the oil-in-water emulsion under predetermined conditions for a predetermined period of time; determining the amount of residue deposited from the oil-in-water emulsion after the predetermined period of time; and determining the oil-in-water emulsion's static stability. A method for determining the dynamic stability of an oil-in-water emulsion comprises the steps of: providing an oil-in-water emulsion; analysing the oil-in-water emulsion at a first time; recirculating the oil-in-water emulsion in a recirculation loop; and analysing the oil-in-water emulsion at second time after recirculation has started; in which the oil-in-water emulsion's dynamic stability is determined based on the analysis at the first and second times. 144.-. (canceled)45. An oil-in-water emulsion for use as a fuel comprising an oil phase and an aqueous phase , at least one primary surfactant selected from ...

SUBSTANCE OR CONTAMINATION DETECTION

A spectroscopic method and system detects the amount of one or more substances or contaminants in or on a product, such as fecal contamination on meat samples. 1. A method for determining an amount of a substance or contaminant in or on each of a series of illuminated products emitting differing levels of light intensity when illuminated , the method comprising the steps of for each product: 'receiving a second signal indicative of intensity of light emitted from the product across a second waveband, said second waveband narrower than the first waveband, said second waveband within the first waveband, and said second waveband containing one or more wavelengths of highest intensity associated with fluorescent properties of the substance or contaminant to be detected,', 'receiving a first signal indicative of intensity of light emitted from the product across a first waveband said first waveband containing one or more wavelengths of highest intensity associated with fluorescent properties of the substance or contaminant to be detected and containing a wider band of other wavelengths emitted from the product,'}determining or predicting a value indicative of the amount of the substance or contaminant in or on the product, from a strength of the first signal and a strength of the second signal and from predetermined information relating to fluorescence behaviour of a same or similar product or a main substance of the product isolated from the substance or contaminant (hereinafter referred to as isolated product) and/or relating to fluorescence behaviour of the substance or contaminant isolated from the product, by separating from the first signal a portion of signal strength relating to the substance or contaminant based on the second signal strength, the fluorescent behaviour of the substance or contaminant in isolation from the product, and the fluorescent behaviour of the isolated product,wherein each product is a meat sample or carcass, and the main substance of the ...

Method of producing paroxetine hydrochloride

The present invention relates to a new process for preparing pharmaceutically active compounds and intermediates therefor. The (-) trans isomer of 4-(4'-fluorophenyl)-3-(3',4'-methylenedioxyphenoxymethyl)piperidine (paroxetine) is an important compound having antidepressant and anti-Parkinson properties. This compound is used in therapy as the hydrochloride salt to treat inter alia depression, obsessive compulsive disorder (OCD) and panic. There is described herein an improved process for its preparation which avoids the generation of impurities caused by the use of strong mineral acid to form the salt.

Examining a diamond

In order to determine whether a blue-to-green diamond (1) has been artificially irradiated or ion bombarded to change its colour, it is irradiated with light of 633 nm wavelength in order to stimulate the emission of luminescence, and luminescence from about 680 to about 800 nm is detected using a confocal microscope (3) and a spectrometer (8) as the focal plane (9) is scanned vertically through the diamond (1). A rapid decrease in luminescence with increase in depth indicates natural irradiation whilst a more rapid decrease indicates ion bombardment. Alternatively, in order to determine whether a diamond (1) is a natural/synthetic doublet, it is irradiated with radiation of 325 nm wavelength in order to stimulate the emission of luminescence, and luminescence from 330 to 450 nm is detected. An abrupt change in luminescence with increase in depth indicates that the diamond is a natural/synthetic doublet.

NEW PAROXETINE SALT, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

NOVEL PAROXETINE SALT, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

L'invention concerne un dérivé de pipéridine nouveau consistant en un sel de paroxétine.Elle concerne également un procédé pour la préparation et les compositions pharmaceutiques le contenant.Application : utilisation de ce composé et de ces compositions pour le traitement de diverses maladies. The present invention relates to a novel piperidine derivative consisting of a paroxetine salt.The invention also relates to a process for the preparation and the pharmaceutical compositions containing it.Application: The use of this compound and these compositions for the treatment of various diseases.

CONNECTION FOR ELECTRICAL CABLES WITH LEAD SHEATH, PAPER INSULATED

Raccord pouvant être posé à l'extrémité d'un câble électrique sous tension élevée dont le diamètre peut avoir une dimension quelconque dans toute une gamme de dimensions, ce câble etant rempli d'huile et comprenant un conducteur, un isolant en papier et une chemise de plomb. Ce raccord est caractérisé par le fait qu'il comprend un manchon 52 en un matériau isolant compris entre une première extrémité 60 et une seconde extrémité 62 et présentant une ouverture longitudinale 68, une partie 54 de fermeture étanche du conducteur 14, solidaire de la première extrémité de ce manchon, une partie 54 de fermeture étanche de la chemise 18 et un élément 102 de réglage des contraintes électriques. A fitting that can be laid at the end of a high voltage electrical cable the diameter of which can be any dimension in a variety of dimensions, the cable being filled with oil and comprising a conductor, paper insulation and a jacket lead. This connector is characterized by the fact that it comprises a sleeve 52 made of an insulating material between a first end 60 and a second end 62 and having a longitudinal opening 68, a part 54 for sealing the conductor 14, integral with the first end of this sleeve, a part 54 for sealing the liner 18 and an element 102 for adjusting the electrical stresses.

Paroxetine compositions

Proactive control system for industrial water systems

A control system is disclosed for monitoring and controlling an industrial water system comprising (a) obtaining a priori knowledge about the correlation between water and treatment chemistry and equipment health, (b) pre-defining a set of operating regions of more than one feed-water or system water variable and at least one chemical treatment variable, where, based on (a) above, corrosion, scaling and fouling are inhibited; (c) adjusting the at least one chemical treatment variable according to the more than one feed water or system water variable, such that based on (a), corrosion, scaling and fouling are inhibited.

PAROXETINMETHANESULFONATE ACETONITRILE SOLVATE 1: 1

Paroxetine methanesulfonate

Process for the preparation of paroxetine hydrochloride acetone solvate

A process for the preparation of paroxetine hydrochloride acetone solvate in which a solution of paroxetine free base in acetone, or a solution of a salt of paroxetine with an organic acid in acetone, is treated with hydrogen chloride gas, and paroxetine hydrochloride acetone solvate is isolated as a crystalline solid.

Examining a diamond.

Paroxetine methanesulfonate, useful in treatment of depression, neuroses and anxiety

Paroxetine methanesulfonate which specified X-ray diffractometry or infrared signals is new. Paroxetine methanesulfonate, which has (i) characteristic infrared signals at 1603, 1513, 1194, 1045, 946, 830, 776, 601, 554 and 539 cm-1 and/or (ii) characteristic X-ray diffractometry signals at 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2 and 31.6 degrees2theta, is new. An Independent claim is included for a medicament comprising 1-200 mg of paroxetine methanesulfonate, based on the free base, and a carrier.

Paroxetine methanesulfonate

Anhydrate forms of a pyridine derivative

The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

Anhydrate forms of a pyridine derivative

A thiazolidinedione derivative and its use as antidiabetic

A novel pharmaceutical compound 5-[-4-[2-methyl-N-(2-pyridyl)amino)ethoxy]thiazolidine-2,4-dione fumarate or a solvate thereof, a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.

Oil-in-water emulsions

Substance or contamination detection

A spectroscopic method and system detects the amount of one or more substances or contaminants in or on a product, such as fecal contamination on meat samples.

Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

A substantially non-hydrated and non-hygroscopic or slightly hygroscopic hydrochloride salts of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; a pharmaceutical composition containing such a compound, a process oF preparing such a compou nd and the use of such a compound in medicine.

Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing the compound

A találmány olyan kristályos formájú paroxetin-metánszulfonátravonatkozik, amely kristályos forma - egyebek mellett - a következőkarakterisztikus IR csúcsokkal rendelkezik: 1603, 1513, 1194, 1045,946, 830, 776, 601, 554 és 539 < 4 cm-1; és/vagy a következőkarakterisztikus XRD csúcsokkal rendelkezik: 8, 3, 10, 5, 15, 6, 16,3, 17, 7, 18, 2, 19, 8, 20, 4, 21, 5, 22, 0, 22, 4, 23, 8, 24, 4, 25,0, 25, 3, 25, 8, 26, 6, 30, 0, 30, 2 és 31, 6 < 0, 2 fok 2 theta. Atalálmány kiterjed a vegyület előállítási eljárására, gyógyászatialkalmazására, valamint a vegyületet tartalmazógyógyszerkészítményekre is. Ó The present invention relates to a crystalline form of paroxetine methane sulfonate having crystalline form having, inter alia, characteristic IR peaks: 1603, 1513, 1194, 1045.946, 830, 776, 601, 554 and 539 <4 cm-1; and / or have the following characteristic XRD peaks: 8, 3, 10, 5, 15, 6, 16.3, 17, 7, 18, 2, 19, 8, 20, 4, 21, 5, 22, 0, 22 , 4, 23, 8, 24, 4, 25.0, 25, 3, 25, 8, 26, 6, 30, 0, 30, 2 and 31, 6 <0, 2 degrees 2 theta. The invention also relates to a process for the preparation of a compound, to a pharmaceutical application thereof, and to a pharmaceutical composition of the compound. HE

Anhydrate forms of a pyridine derivative

The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

Sodium salts of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt, or a pharmaceutically acceptable solvate thereof, characterised in that the sodium salt is non-hygroscopic or slightly hygroscapic; a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

Proactive control system for an industrial water system

A control system is disclosed for monitoring and controlling an industrial water system comprising (a) obtaining a priori knowledge about the correlation between water and treatment chemistry and equipment health; (b) pre-defining a set of operating regions of more than one feed-water or system water variable and at least one chemical treatment variable, where, based on (a) above, corrosion, scaling and fouling are inhibited; (c) adjusting the at least one chemical treatment variable according to the more than one feed water or system water variable, such that based on (a), corrosion, scaling and fouling are inhibited.

Novel compound.

Paroxetine methanesulfonate

Paroxetine methanesulfonate, processes for preparing it pharmaceutical compositions comprising it and its use in therapy are disclosed.

Method and apparatus for producing a hydrogen-containing product

Process and apparatus for producing a hydrogen-containing product by steam-hydrocarbon reforming of multiple hydrocarbon feedstocks in a production facility utilizing a prereformer in addition to the primary reformer. The temperature of the reactant mixture introduced into the prereformer is controlled depending on the composition of the reactant mixture fed to the prereformer.

Method of forming a containment system for an absorbent article

Elastic elements (depicted as the round cords) are bonded near the respective edges of a longitudinal substrate 240 which is then subjected to progressive bonding and edge folding operations and then slit down the middle 246 to form a pair of leakage guards 44, 46. These respective guards are then bonded each along and inwardly of the respective longitudinal side of the absorbent base pad and, in particular, in the region of the ends of the pad but not in the crotch region. The lateral flaps that project from the distal end of the stem portion of the flaps are bonded to the stem portions.

Hydrochloride salts of-5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, method for their production and pharmaceutical compositions containing them

A találmány olyan 5-[4-{2-[N-metil-N-(2-piridil)-amino]etoxi}-benzil]-2,4-dioxo-tiazolidin-hidrokloridokra vonatkozik, amelyekre azjellemző, hogy (i) olyan infravörös spektrumokat eredményeznek,amelyek körülbelül 1745, 1516, 1257, 1056 és 803 cm-l-nél tartalmaznakcsúcsokat; (ii) olyan por-röntgendiffrakciós (XRPD) képeketeredményeznek, amelyek körülbelül 10,1, 13,4, 17,2, 22,2 és 29,4 °2qdiffrakciós szögeknél tartalmaznak csúcsokat; és/vagy (iii) olyanRaman-spektrumokat eredményeznek, amelyek körülbelül 1314, 1242, 118,918 és 404 cm-l-nél tartalmaznak csúcsokat. A találmány kiterjed ahidrokloridok előállítási eljárására, gyógyászati alkalmazására és ahidrokloridokat tartalmazó gyógyszerkészítményekre is. Ó The present invention relates to 5- [4- {2- [N-methyl-N- (2-pyridyl) amino] ethoxy} benzyl] -2,4-dioxothiazolidine hydrochlorides, characterized in that (i) produce infrared spectra that have peaks at about 1745, 1516, 1257, 1056 and 803 cm -1; (ii) produce powder X-ray diffraction (XRPD) images having peaks at approximately 10.1, 13.4, 17.2, 22.2, and 29.4 ° 2d diffraction angles; and / or (iii) results in Raman spectra having peaks at about 1314, 1242, 118.918 and 404 cm -1. The invention also relates to a process for the preparation of the hydrochloride, to its use in medicine and to pharmaceutical compositions containing the hydrochloride. SHE

Tartrate salt of thiazolidinedione derivative, process for its preparation, use thereof, and pharmaceutical composition comprising the salt

Wear reduction device for rotary solids handling equipment

A pump for solids handling is provided having a suction liner in combination with an impeller. The suction liner has a spiral design. The impeller has forward curved impeller suction side pump out vanes. The suction liner spiral design and the forward curved impeller suction side pump out vanes are configured to handle solids having a weight concentration (Cw) < about 40% and/or a solids size distribution < about 200 microns, and to exclude abrasive solids from an impeller/suction side liner gap by increasing the resistance to slurry flow from a high pressure area at the periphery of the impeller, and expel the solids that do manage to enter the impeller/suction side liner gap by guiding the solids away from a suction eye of the impeller, so abrasive erosion is substantially prevented and a tight clearance is substantially maintained at the impeller/suction side liner gap between the impeller and the suction liner.

Quinazoline Salt Compounds

Salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity.

Complexes of 6.alpha. 9.alpha. - difluoro - 17. alpha. - [ (2 - furanylcarbonyl) oxy] - 11.beta. -hydroxy - 16- .alpha. -methyl - 3oxo- androsta- 1,4 -diene - 17 .beta. -carbothioic acid s-fluoromethyl ester

There is provided a crystalline chemical complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in the crystalline complex is of space group P212121 having unit cell dimensions of about 7.6 ± 0.6 Å, 12.7 ± 0.7 Å, and 33 ± 3 Å when determined at 120K.

Examining a Gemstone

Paroxetine salts, process for their preparation, pharmaceutical compositions comprising these and uses thereof

Paroxetine methanesulfonate

Isolating valve for fluid handling equipment (e.g. a water meter)

A valve which may be used to isolate fluid handling equipment. A valve having inlet and outlet passageway (17 and 18) is provided with a means (14) for mounting fluid handling equipment between the two passageways and a valve member (20) for closing the said two passageways (17, 18). The valve member comprises a plate with a pair of apertures (25, 27) and is rotatable between positions in which the apertures are aligned with or obstruct the passageways. The inlet and outlet passageways (17 and 18) may be either co-axial (Fig 1) or spatially separated (Fig 4, not shown). The embodiment of figure 1 includes a screw threaded spigot (5) which enables the valve to be mounted on the body of a conventional stop valve from which the head works have been removed. <IMAGE>

Wear reduction device for rotary solids handling equipment

A pump for solids handling is provided having a suction liner in combination with an impeller. The suction liner has a spiral design. The impeller has forward curved impeller suction side pump out vanes. The suction liner spiral design and the forward curved impeller suction side pump out vanes are configured to handle solids having a weight concentration (Cw) < about 40% and/or a solids size distribution < about 200 microns, and to exclude abrasive solids from an impeller/suction side liner gap by increasing the resistance to slurry flow from a high pressure area at the periphery of the impeller, and expel the solids that do manage to enter the impeller/suction side liner gap by guiding the solids away from a suction eye of the impeller, so abrasive erosion is substantially prevented and a tight clearance is substantially maintained at the impeller/suction side liner gap between the impeller and the suction liner.

A DERIVATIVE OF TIAZOLIDINADIONA AND ITS USE AS AN ANTIDIABETIC.

Sal de etanosulfonato de 5-[4-[2-(N-metil-N-(2- piridil)amino)etoxi]-bencil]tiazolidin-2, 4-diona o un solvato del mismo.

SALES TARTRATO DE DERIVADO DE TIAZOLIDINADIONA.

Un compuesto 5-[4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]-tiazolidin-2,4-diona, sal de D(-) tartrato o un solvato del mismo. A 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] -thiazolidin-2,4-dione compound, D (-) tartrate salt or a solvate thereof.

Process for the preparation of paroxetine acetate and analogues thereof

The present invention relates to a new process for preparing pharmaceutically active compounds and intermediates therefor. The (-) trans isomer of 4-(4'-fluorophenyl)-3-(3',4'-methylenedioxyphenoxymethyl)-piperidine (paroxetine) is an important compound having antidepressant and anti-Parkinson properties. This compound is used in therapy as the hydrochloride salt to treat inter alia depression, obsessive compulsive disorder (OCD) and panic. There is described a process for the preparation of paroxetine acetate and analogues thereof.

SYNTHETIC DIAMOND WITH HIGH CRYSTALLINE QUALITY

Crystalline form of paroxetine.

Saf,solvent içermeyen, örnegin kristalin paroksetin serbest bazi ve bunun depresyon tedavisindeki kullanimi. Pure, solvent-free, for example, crystalline paroxetine free base and its use in the treatment of depression.

Method and apparatus for producing a hydrogen-containing product

Process and apparatus for producing a hydrogen-containing product by steam-hydrocarbon reforming of multiple hydrocarbon feedstocks in a production facility utilizing a prereformer in addition to the primary reformer. The temperature of the reactant mixture introduced into the prereformer is controlled depending on the composition of the reactant mixture fed to the prereformer.

5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical

Paroxetine methanesulfonate

Hydrogen production system and process

Hydrogen production process and apparatus using a combined stream of gas turbine exhaust from a gas turbine and combustion air from forced draft fan as combustion oxidant in a steam reforming furnace. A valve assembly for providing draft air is included to quickly provide additional combustion air to the reformer furnace when the gas turbine unexpectedly shuts down.

Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.

Anhydrate forms of a pyridine derivative

The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

proactive control system for an industrial water system

A method of improving the crystalline perfection of diamond crystals

Paroxetine methanesulfonate

Crystalline form of paroxetine

Barrier flap for an absorbent article

Paroxetine salts, pharmaceutical preparation containing these and uses thereof

Hydrogen production system and process

Hydrogen production process and apparatus using a combined stream of gas turbine exhaust from a gas turbine and combustion air from forced draft fan as combustion oxidant in a steam reforming furnace. A valve assembly for providing draft air is included to quickly provide additional combustion air to the reformer furnace when the gas turbine unexpectedly shuts down.

The hydrochloride salt of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione

Paroxetine methanesulfonate acetonitrile solvate 1:1

PAROXETINE SALT COMPOUNDS, THEIR PREPARATION AND USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Compuestos de sales de paroxetina, su preparación y uso, y composiciones farmacéuticas que los contienen. Los compuestos comprende metanosulfonato de paroxetina en forma cristalina. El procedimiento comprende cristalizar o recristalizar una solución de metanosulfonato de paroxetina en un disolvente. Los compuestos pueden usarse en la preparación de un medicamento. Las composiciones comprenden metanosulfonato de paroxetina y un vehículo farmacéuticamente aceptable. La invención es aplicable al tratamiento y/o prevención de alcoholismo, depresión, ansiedad, anorexia y otros trastornos médicos. Compounds of paroxetine salts, their preparation and use, and pharmaceutical compositions containing them. The compounds comprise paroxetine methanesulfonate in crystalline form. The process comprises crystallizing or recrystallizing a solution of paroxetine methanesulfonate in a solvent. The compounds can be used in the preparation of a medicament. The compositions comprise paroxetine methanesulfonate and a pharmaceutically acceptable carrier. The invention is applicable to the treatment and / or prevention of alcoholism, depression, anxiety, anorexia and other medical disorders.

INFLAMMATORY BZW. ANTIALLERGIC ANDROSTANTEX COMPLEXES

The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

A novel pharmaceutical compound 5-[4-[2-(N-methly-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride, a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.

5- (4- (2- (N-METHYL-N- (2-PYRIDIL) AMINO)) ETHOXY) BENZYL) THIAZOLIDINE-2, 4-DIONE IODHYDRIC AS A PHARMACEUTICAL PRODUCT

Tartrate salts of thiazolidinedione derivative

Paroxetine compositions

Přítomné řešení se týká paroxetinové kompozice, ve které je paroxetin adsorbován na nosič, za účelem přípravy volně tekoucího prášku vhodného pro plnění do kapslí nebo pro přípravu tablet, a použití této kompozice pro terapii deprese. The present invention relates to a paroxetine composition in which it is paroxetine adsorbed onto the carrier to prepare freely flowable powder suitable for filling into capsules or pro tablet preparation, and use of the composition for depression therapy.

Process for the production of paroxetine hydrochloride acetone solvate

Crystalline paroxetine hydrochloride acetone solvate having a modified habit that is more easily desolvated to form the anhydrate is obtained by crystallising from a solution of paroxetine hydrochloride in acetone to which has been added a habit modifier compound. Form A anhydrate is obtained by heating the crystalline solvate of modified habit in a vacuum oven. Suitable habit modifiers are carboxylic acids and amine salts.

Thiazolidinedione salt for treatment of diabetes mellitus

A novel pharmaceutical compound 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrobromide or a solvate thereof, a process for preparing such a compound, a pharmaceutical compositi on comprising such a compound and the use of such a compound in medicine.</SDOA B>

Sodium salt of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)-ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition in which the salt is comprised

A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt, or a pharmaceutically acceptable solvate thereof, characterised in that the sodium salt is non-hygroscopic or slightly hygroscopic; a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

Paroxetine compositions

Tartrate salts of thiazolidinedione derivative

A novel pharmaceutical compound 5-[4-2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Meso- Tartrate or a solvate thereof, a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.

Tartrate salts of thiazolidinedione derivative.

A novel pharmaceutical compound 5-[4-2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Meso- Tartrate or a solvate thereof, a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.

Paroxetine derivatives

Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.

Paroxetine methanesulfonate

Paraxetine methanesulfonate is a novel compound having pharmaceutical activity. It may be obtained as a 1:1 solvate with acetonitrile and it can be converted to paroxetine hydrochloride.

Crystalline form of paroxetine

Pure, solvent-free, for example crystalline, paroxetine free base; and its use in therapy to treat depression.

Substantially non-hydrated and non-hygroscopic or slightly hygroscopic hydrochloride salt of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, method for its preparation, pharmaceutical composition containing thereof and its use

Hydrochloride salt of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione provides an infra red spectrum containing peaks at about 1745, 1516, 1257, 1056 and 803 cm-1, provides an X-ray powder diffraction pattern containing peaks at about 10.1, 13.4, 17.2, 22.2 and 29.4 °2theta and/or provides a Raman spectrum, containing peaks at about 1314, 1242, 1185, 918 and 404 cm-1 .

Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.

Paroxetine methanesulfonate

Paroxetine methanesulfonate, processes for preparing it pharmaceutical compositions comprising it and its use in therapy are disclosed.

Paroxetine compositions

Mixed paroxetine propan-2-ol solvates

A crystalline paroxetine hydrochloride mixed solvate, that is more easily desolvated than the propan-2-ol solvate to form the anhydrate, is obtained by contacting crystalline propan-2-ol solvate with a transformation solvent. Suitable transformation solvents are an ether, ketone, chlorinated hydrocarbon, nitrile, lower alcohol, or ester, or a mixture thereof. Crystalline paroxetine hydrochloride anhydrate is obtained by heating the mixed solvate in a vacuum oven.

5-'4-'2-(N-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione mesylate salt

TARTRATE SALT OF A THIAZOLIDINEDIONE DERIVATIVE

New pharmaceutical preparation

Hydrochloride salts of 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione

Paroxetine compositions.

Bu bulus, kapsül doldurma veya tablet olusturma için faydali olan serbest akiskan bir toz olusturmak için bir tasiyici üzerine abzorbe edilen ve depresyon tedavisinde kullanilan paroksetin ile ilgilidir. This invention relates to paroxetine which is absorbed onto a carrier and used to treat depression, to form a free-flowing powder useful for capsule filling or tabletting.

A thiazolidinedione derivative and its use as an antidiabetic agent

A carton lidding and stacking apparatus and process

A process of manipulating a closable carton with lid panels extending from walls of the carton and tabs received in slots formed in the lid panels to secure the lid panels to close the carton. The process has a step of moving a folding element transverse to each wall from which a lid extends to move the one or more lids into a position which closes the carton. The process has a step of lifting the closed carton past a non-return support and into engagement with another carton to provide a stack of closed cartons supported by the non-return support. The process has a step of the support then releasing a stack of closed cartons to a conveyor.

Thiazolidinedione derivative in the form of a tartaric acid salt

A novel pharmaceutical compound 5-[4-2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Meso- Tartrate or a solvate thereof, a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.

THIAZOLIDINEDIONE DERIVATIVE TARTRATE SALTS

Instrument for examining a gemstone

The instrument has a housing (1) mounting the following components to provide a self-contained, stand-alone instrument: a compact solid state 532nm laser 9 coupled to a window (5) in a thermally-insulated container (2) for liquid nitrogen and the gemstone (4); a compact solid state diode 655 nm laser (10) coupled to the window (5); two compact, sensitive CCD spectrometers 11a and 11b detecting luminescence features with zero-phonon lines at in the range 550-1000 nm; a processor (17) for processing the signals from the spectrometers 11a and 11b to indicate whether the gemstone (4) is a natural diamond which has not been subjected to irradiation treatment or hgih-pressure high-temperature treatment; and a display (18). The container (2) has a cover (6) and a pin (8) which is used to place and hold the gemstone (4) against the window (5).